NRx Pharmaceuticals
Stock Forecast, Prediction & Price Target
NRx Pharmaceuticals Financial Estimates
NRx Pharmaceuticals Revenue Estimates
NRx Pharmaceuticals EBITDA Estimates
NRx Pharmaceuticals Earnings per Share Estimates
| Passed | Analyst forecast | ||||||
|---|---|---|---|---|---|---|---|
| Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2025 | 12/31/2026 | 12/31/2027 | 12/31/2028 |
Revenue
% change YoY
| $0 N/A | $0 0% | $0 0% | Avg: $20.9M Low: $20.9M High: $20.9M avg. 0% | Avg: $50M Low: $50M High: $50M avg. 139.23% | Avg: $200M Low: $200M High: $200M avg. 300% | Avg: $300M Low: $300M High: $300M avg. 50% |
Net Income
% change YoY
| $-71.71M N/A | $-35.23M 50.86% | $-30.15M 14.43% | Avg: $-21.3M Low: $-15.90M High: $-15.90M avg. 29.35% | Avg: $9.84M Low: $9.84M High: $9.84M avg. 146.23% | Avg: $49.24M Low: $49.24M High: $49.24M avg. 400% | Avg: $7.50M Low: $7.50M High: $7.50M avg. -84.76% |
EBITDA
% change YoY
| $-115.79M N/A | $-44.65M 61.43% | $-30.02M 32.75% | Avg: $0 Low: $0 High: $0 avg. 100% | Avg: $0 Low: $0 High: $0 avg. 0% | Avg: $0 Low: $0 High: $0 avg. 0% | Avg: $0 Low: $0 High: $0 avg. 0% |
EPS
% change YoY
| -$1.53 N/A | -$0.54 64.70% | -$3.98 -637.03% | Avg: -$2.1 Low: -$2.1 High: -$2.1 avg. 47.23% | Avg: $1.3 Low: $1.3 High: $1.3 avg. 161.90% | Avg: $6.5 Low: $6.5 High: $6.5 avg. 400% | Avg: $0.99 Low: $0.99 High: $0.99 avg. -84.76% |
Operating Expenses
% change YoY
| $94.43M N/A | $44.39M -52.98% | $27.58M -37.87% | Avg: $0 Low: $0 High: $0 avg. -100% | Avg: $0 Low: $0 High: $0 avg. 0% | Avg: $0 Low: $0 High: $0 avg. 0% | Avg: $0 Low: $0 High: $0 avg. 0% |
FAQ
What is NRx Pharmaceuticals stock earnings growth forecast?
Wall Street analysts estimate the annual average earnings growth rate of 122.70% in 2025-2028.
We have gathered data from 1 analysts. Their low estimate is -15.90M, average is -21.3M and high is -15.90M.
What is NRx Pharmaceuticals stock revenue growth forecast?
Wall Street analysts forecast annual average revenue growth of 122.30% in 2025-2028.
We have gathered data from 1 analysts. Their low revenue estimate is $20.9M, average is $20.9M and high is $20.9M.
What is NRx Pharmaceuticals stock earnings per share growth forecast?
Wall Street analysts forecast annual average earnings growth of 131.09% in 2025-2028.
We have gathered data from 1 analysts. Their low earnings per share estimate is -$2.1, average is -$2.1 and high is $-2.1.
What is the best performing analyst?
In the last twelve months analysts have been covering NRx Pharmaceuticals stock. The most successful analyst is Vernon Bernardino whose win rate is 100%. He has correctly predicted 1/1 price targets.